Qiong Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qiong Zhu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Deyu Yuan
Department of Ultrasound, Xinqiao Hospital, Army Medical University, 400037 Chongqing, China
1 shared publication - Haiyan Li
Department of Ultrasound, Xinqiao Hospital, Army Medical University, 400037 Chongqing, China
1 shared publication Hui Li
Army Medical University, Xinqiao Hospital Department of Ultrasound Chongqing, 400037
1 shared publication- Hui Li
Department of Ultrasound, Xinqiao Hospital Army Medical University Chongqing China
1 shared publication Jingzhen Zhu
Army Medical University, Xinqiao Hospital Department of Urology Chongqing, 400037
1 shared publication- Junhui Tang
Department of Ultrasound, the General Hospital of Tibet Military Command
1 shared publication
Latest Publications
- 16 October 2025
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 136 (11)
Transthoracic ultrasound with microbubble therapy modulates gut microbiota and protects against hypoxia-induced pulmonary hypertension in mice
Aims: Recent developments have revealed gut microbiota is involved in the development of high-altitude pulmonary hypertension (HAPH). As ultrasound-targeted microbubble destruction (UTMD) can augment tissue perfusion, it might influence the HAPH. Therefore, this study explored the effects of UTMD on gut microbiota tentatively, emphasizing the impact of UTMD on HAPH. Methods and results: Fifteen mice were divided into normoxia (Nor), hypoxia (Hyp), and UTMD-treated (Hyp + UTMD) groups. The Nor group was raised under normobaric normoxia, whereas Hyp was placed in a hypoxic chamber simulating low oxygen levels at high altitude. The Hyp + UTMD group was placed in the same chamber with UTMD exposed every three days for 8 w. Fecal samples of mice in each group were collected at 4 and 8 w, and all mice were subjected to a hemodynamic assay on 57th day for right ventricle systolic pressure (RVSP) monitoring, which could have direct and lasting physiological effects on the nervous, cardiovascular, respiratory, and digestive systems. 16S rRNA sequencing analysis revealed gut microbiota modification in both Hyp and Hyp + UTMD. The Firmicutes/Bacteroidetes ratio in Hyp1 (75.97%) was significantly higher than that in Nor (43.70%) and Hyp + UTMD1 (24.55%). Compared with microbiota in Hyp1, 3 bacterial phyla were increased, including p_Bacteroidetes, p_Epsilonbacteraeota, and p_Verrucomicrobia, whereas p_Firmicutes was decreased in Hyp + UTMD1. And g_Alloprevotella was significantly upregulated in Hyp + UTMD1 and Hyp + UTMD2, which was downregulated in the Hyp. Hyp + UTMD RVSP (29.7 mmHg) was significantly suppressed when compared to Hyp (36.5 mmHg), and g_Alloprevotella exhibited a significant negative correlation with RVSP. Conclusion: UTMD-mediated modification of the gut microbiota suppresses the development of hypoxic-induced HAPH, highlighting the potential of UTMD treatment that modulate gut microbiota to prevent hypoxic pulmonary hypertension.
- 16 October 2025
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 136 (11)
Transthoracic ultrasound with microbubble therapy modulates gut microbiota and protects against hypoxia-induced pulmonary hypertension in mice
Aims: Recent developments have revealed gut microbiota is involved in the development of high-altitude pulmonary hypertension (HAPH). As ultrasound-targeted microbubble destruction (UTMD) can augment tissue perfusion, it might influence the HAPH. Therefore, this study explored the effects of UTMD on gut microbiota tentatively, emphasizing the impact of UTMD on HAPH. Methods and results: Fifteen mice were divided into normoxia (Nor), hypoxia (Hyp), and UTMD-treated (Hyp + UTMD) groups. The Nor group was raised under normobaric normoxia, whereas Hyp was placed in a hypoxic chamber simulating low oxygen levels at high altitude. The Hyp + UTMD group was placed in the same chamber with UTMD exposed every three days for 8 w. Fecal samples of mice in each group were collected at 4 and 8 w, and all mice were subjected to a hemodynamic assay on 57th day for right ventricle systolic pressure (RVSP) monitoring, which could have direct and lasting physiological effects on the nervous, cardiovascular, respiratory, and digestive systems. 16S rRNA sequencing analysis revealed gut microbiota modification in both Hyp and Hyp + UTMD. The Firmicutes/Bacteroidetes ratio in Hyp1 (75.97%) was significantly higher than that in Nor (43.70%) and Hyp + UTMD1 (24.55%). Compared with microbiota in Hyp1, 3 bacterial phyla were increased, including p_Bacteroidetes, p_Epsilonbacteraeota, and p_Verrucomicrobia, whereas p_Firmicutes was decreased in Hyp + UTMD1. And g_Alloprevotella was significantly upregulated in Hyp + UTMD1 and Hyp + UTMD2, which was downregulated in the Hyp. Hyp + UTMD RVSP (29.7 mmHg) was significantly suppressed when compared to Hyp (36.5 mmHg), and g_Alloprevotella exhibited a significant negative correlation with RVSP. Conclusion: UTMD-mediated modification of the gut microbiota suppresses the development of hypoxic-induced HAPH, highlighting the potential of UTMD treatment that modulate gut microbiota to prevent hypoxic pulmonary hypertension.
- Open Access
- 28 September 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (9)
Effects of Hormones on Left Heart Structure and Function with Echocardiography in Acromegaly
Background: The relationship between growth hormone (GH) and changes in cardiac morphology and function in the current study has not been fully elucidated, and this study aimed to assess the effect of hormonal factors on left ventricular structure and function in acromegaly patients using echocardiography. Methods: We retrospectively analyzed the relationships between various echocardiographic parameters in 117 pre-treatment patients with acromegaly and four hormonal variables: GH, GH nadir during the oral glucose tolerance test (OGTT-GH), insulin-like growth factor-1 (IGF-1), and IGF-1/upper limit of normal (IGF-1/ULN) adjusted for age and sex. Patients were categorized into normal and abnormal subgroups based on interventricular septal (IVS) thickening, left atrial (LA) enlargement, and left ventricular (LV) abnormal LV peak flow velocities E and A (E/A ratios). Furthermore, the hormonal levels within these subgroups were compared. Results: Correlation analysis revealed that IGF-1/ULN was positively associated with IVS thickening and LA enlargement (p = 0.003 and p = 0.001), and negatively associated with an abnormal LV E/A ratio (p < 0.001). Regression analysis identified IGF-1/ULN as a significant risk factor for left heart alterations. Among the four hormonal variables, IGF-1/ULN demonstrated the largest area under the receiver operating characteristic (ROC) curve (AUC), with values of 0.628 for IVS thickening, 0.701 for LA enlargement, and 0.653 for LV abnormal E/A ratio. Conclusion: IGF-1/ULN is strongly associated with changes in left heart structure and function in acromegaly and serves as a risk factor for these alterations. Thus, monitoring IGF-1/ULN may help predict cardiac changes via echocardiography, suggesting that early clinical management of GH-related levels could prevent early cardiac abnormalities in patients with acromegaly.
- 28 September 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (9)
Open AccessEffects of Hormones on Left Heart Structure and Function with Echocardiography in Acromegaly
Background: The relationship between growth hormone (GH) and changes in cardiac morphology and function in the current study has not been fully elucidated, and this study aimed to assess the effect of hormonal factors on left ventricular structure and function in acromegaly patients using echocardiography. Methods: We retrospectively analyzed the relationships between various echocardiographic parameters in 117 pre-treatment patients with acromegaly and four hormonal variables: GH, GH nadir during the oral glucose tolerance test (OGTT-GH), insulin-like growth factor-1 (IGF-1), and IGF-1/upper limit of normal (IGF-1/ULN) adjusted for age and sex. Patients were categorized into normal and abnormal subgroups based on interventricular septal (IVS) thickening, left atrial (LA) enlargement, and left ventricular (LV) abnormal LV peak flow velocities E and A (E/A ratios). Furthermore, the hormonal levels within these subgroups were compared. Results: Correlation analysis revealed that IGF-1/ULN was positively associated with IVS thickening and LA enlargement (p = 0.003 and p = 0.001), and negatively associated with an abnormal LV E/A ratio (p < 0.001). Regression analysis identified IGF-1/ULN as a significant risk factor for left heart alterations. Among the four hormonal variables, IGF-1/ULN demonstrated the largest area under the receiver operating characteristic (ROC) curve (AUC), with values of 0.628 for IVS thickening, 0.701 for LA enlargement, and 0.653 for LV abnormal E/A ratio. Conclusion: IGF-1/ULN is strongly associated with changes in left heart structure and function in acromegaly and serves as a risk factor for these alterations. Thus, monitoring IGF-1/ULN may help predict cardiac changes via echocardiography, suggesting that early clinical management of GH-related levels could prevent early cardiac abnormalities in patients with acromegaly.